Autonomix Medical, Inc. (NASDAQ: AMIX) Announces Release of the Next CEO Corner Segment
Autonomix Medical (NASDAQ: AMIX), a medical device company focusing on innovative technologies for nervous system diseases, has released a new CEO Corner segment. The segment, featuring CEO Brad Hauser, discusses the company's recent licensing agreement with RF Innovations for the intellectual property of the Apex 6 Radiofrequency Generator. This transaction marks a significant step in Autonomix's mission to revolutionize the diagnosis and treatment of nervous system disorders. The CEO Corner segment is now available on the company's website, providing investors and stakeholders with insights into this strategic move and its potential impact on Autonomix's future developments.
Autonomix Medical (NASDAQ: AMIX), un'azienda di dispositivi medici focalizzata su tecnologie innovative per le malattie del sistema nervoso, ha pubblicato un nuovo segmento del CEO Corner. In questo segmento, il CEO Brad Hauser discute del recente accordo di licenza con RF Innovations per la proprietà intellettuale del Apex 6 Radiofrequency Generator. Questa transazione rappresenta un passo significativo nella missione di Autonomix di rivoluzionare la diagnosi e il trattamento dei disturbi del sistema nervoso. Il segmento CEO Corner è ora disponibile sul sito web dell'azienda, fornendo a investitori e stakeholder approfondimenti su questa mossa strategica e sul suo potenziale impatto sui futuri sviluppi di Autonomix.
Autonomix Medical (NASDAQ: AMIX), una empresa de dispositivos médicos centrada en tecnologías innovadoras para enfermedades del sistema nervioso, ha lanzado un nuevo segmento de CEO Corner. En este segmento, el CEO Brad Hauser discute el reciente acuerdo de licencia con RF Innovations para la propiedad intelectual del Apex 6 Radiofrequency Generator. Esta transacción marca un paso significativo en la misión de Autonomix de revolucionar el diagnóstico y tratamiento de trastornos del sistema nervioso. El segmento de CEO Corner ya está disponible en el sitio web de la empresa, brindando a inversores y partes interesadas información sobre este movimiento estratégico y su impacto potencial en los futuros desarrollos de Autonomix.
오토노믹스 메디컬 (NASDAQ: AMIX), 신경계 질환을 위한 혁신적인 기술에 집중하는 의료기기 회사가 새로운 CEO 코너 세그먼트를 발표했습니다. 이 세그먼트에서 CEO 브래드 하우저는 RF 이노베이션과의 Apex 6 라디오 주파수 발생기에 대한 지적 재산권 라이센스 계약에 대해 논의합니다. 이 거래는 오토노믹스의 신경계 장애의 진단 및 치료 혁신이라는 사명에 중요한 이정표가 됩니다. CEO 코너 세그먼트는 이제 회사 웹사이트에서 제공되며, 투자자와 이해관계자들에게 이 전략적 움직임과 오토노믹스의 미래 발전에 미칠 잠재적인 영향에 대한 통찰을 제공합니다.
Autonomix Medical (NASDAQ: AMIX), une entreprise de dispositifs médicaux axée sur des technologies innovantes pour les maladies du système nerveux, a publié un nouveau segment du Coin du PDG. Dans ce segment, le PDG Brad Hauser aborde le récent accord de licence avec RF Innovations pour la propriété intellectuelle du Apex 6 Radiofrequency Generator. Cette transaction marque une étape importante dans la mission d'Autonomix de révolutionner le diagnostic et le traitement des troubles du système nerveux. Le segment Coin du PDG est désormais disponible sur le site Web de l'entreprise, offrant aux investisseurs et aux parties prenantes un aperçu de ce mouvement stratégique et de son impact potentiel sur les futurs développements d'Autonomix.
Autonomix Medical (NASDAQ: AMIX), ein Medizintechnikunternehmen, das sich auf innovative Technologien für Erkrankungen des Nervensystems konzentriert, hat ein neues CEO Corner-Segment veröffentlicht. In diesem Segment spricht CEO Brad Hauser über die kürzlich vereinbarte Lizenzvereinbarung mit RF Innovations zur geistigen Eigentum des Apex 6 Radiofrequency Generator. Diese Transaktion stellt einen bedeutenden Schritt in der Mission von Autonomix dar, die Diagnose und Behandlung von Nervenerkrankungen zu revolutionieren. Das CEO Corner-Segment ist jetzt auf der Website des Unternehmens verfügbar und bietet Investoren und Interessengruppen Einblicke in diesen strategischen Schritt und dessen potenzielle Auswirkungen auf die zukünftigen Entwicklungen von Autonomix.
- Licensing agreement for Apex 6 Radiofrequency Generator intellectual property
- Strategic expansion of technology portfolio in nervous system disease treatment
- None.
THE WOODLANDS, TX, Aug. 02, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced the next CEO Corner segment has been published on the Company’s website. For the CEO Corner segment, Brad Hauser, CEO of Autonomix, discussed the Company’s recently completed transaction with RF Innovations, Inc., a privately held medical technology company, to license the intellectual property to its Apex 6 Radiofrequency Generator.
The CEO Corner segment is now available here.
About Autonomix Medical, Inc.
Autonomix is a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated. The Company’s first-in-class technology platform includes a catheter-based microchip sensing array that has the ability to detect and differentiate neural signals with approximately 3,000 times greater sensitivity than currently available technologies. We believe this will enable, for the first time ever, transvascular diagnosis and treatment of diseases involving the peripheral nervous system virtually anywhere in the body.
We are initially developing technology for the treatment of pain, with initial trials focused on pancreatic cancer, a condition that causes debilitating pain and is without a reliable solution. Our technology constitutes a platform to address dozens of indications, including cardiology, hypertension and chronic pain management, across a wide disease spectrum. Our technology is investigational and has not yet been cleared for marketing in the United States.
For more information, visit autonomix.com and connect with the Company on X, LinkedIn, Instagram and Facebook.
Investor and Media Contact
JTC Team, LLC
Jenene Thomas
833-475-8247
autonomix@jtcir.com
FAQ
What did Autonomix Medical (AMIX) announce on August 2, 2024?
Who is featured in Autonomix Medical's (AMIX) latest CEO Corner segment?
What recent transaction did Autonomix Medical (AMIX) complete with RF Innovations?
Where can investors find Autonomix Medical's (AMIX) new CEO Corner segment?
